A Phase 3 interventional study of Esketamine 56 mg and Esketamine 84 mg in Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development, LLC. Completed at 30 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 11 in phase 3, and was the 9th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, China, Japan and 1 more country
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
The George Institute · Sites in Australia
Ages 18+
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 210 across the 18 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson: 1 open now, 1 under way, 1 of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 3, and was the 15th registered.
Johnson & Johnson’s Depressive Disorder, Treatment-Resistant studies by the year they started, since 2010.
1 of the studies testing esketamine in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06278779The George InstituteComparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 21 in Depressive Disorder, Treatment-Resistant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal esketamine (56 milligram [mg] or 84 mg) plus a newly initiated oral antidepressant compared with switching to a newly initiated oral antidepressant (active comparator) plus intranasal placebo, in improving depressive symptoms. Efficacy will be assessed by the change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score from Day 1 (before randomization) to the end of the 4-week double-blind treatment phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant's depressive symptoms have previously demonstrated non-response to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral Antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
Drug: Placebo · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral Antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Participants will self-administer 56 mg of esketamine as intranasal spray.
Participants will self-administer 84 mg of esketamine as intranasal spray.
Participants will self-administer matching placebo as intranasal spray.
Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline up to end of the double-blind treatment phase (Day 28)
Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1: predose) to 24 hours post first dose (Day 2)
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)
The SDS is a subject-reported outcome measure that consists of a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when underproductive.
Time frame: Baseline up to end of the double-blind treatment phase (Day 28)
Percentage of Participants With Onset of Clinical Response
Onset of clinical response is defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in MADRS total score with onset by Day 2 that was maintained through Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Day 2 up to Day 28
Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)
Percentage of responders at the end of double-blind treatment phase (Day 28) were assessed. A participant was defined as a responder at a given time point if the percent improvement from baseline in MADRS total score is at least 50%. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Day 28
Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)
Percentage of participants in remission at the end of double-blind treatment phase (Day 28) were assessed. A participant was considered as a remitter if participant had a MADRS total score of less than or equal to \[\<=\] 12 at a visit. MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Day 28
Percentage of Participants With Sustained Remission
Sustained remission is defined as the first occurrence of remission (MADRS Total score \<=12) that was maintained through the Day 28 assessment with one excursion prior to Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Up to Day 28
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S permits a global evaluation of the participant's condition at a given time. Negative change in score indicates improvement. The last post-baseline observation during the double-blind phase was carried forward as Endpoint.
Time frame: Baseline up to Double-blind Endpoint (Day 28)
Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
The GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). The last post-baseline observation during the double-blind phase was carried forward as the "Endpoint".
Time frame: Baseline up to Endpoint (double-blind treatment phase [Day 28])
Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index
The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate problems, Level 4 indicating severe problems, and Level 5 indicating extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. Health Status Index ranges from -0.148 to 0.949, and is anchored at 0 (dead) and 1 (full health), a lower score indicates worse health.
Time frame: Baseline up to Double-blind Endpoint (Day 28)
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)
The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.
Time frame: Baseline up to Double-blind Endpoint (Day 28)
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.
Time frame: Baseline up to Double-blind Endpoint (Day 28)
| Milestone | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Started | 126 | 126 |
| Full analysis set | 124 | 126 |
| Completed | 108 | 106 |
| Not completed | 18 | 20 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lack of efficacy | 3 | 14 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Covid-19 related | 2 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Other | 2 | 0 |
| Milestone | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Started | 106 | 103 |
| Completed | 99 | 100 |
| Not completed | 7 | 3 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Investigator decision to discontinue follow-up and proceed to 54135419trd3008 (nct02782104) | 1 | 0 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28) | -10.1 ± 10.80 | -8.1 ± 10.26 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2) | -8.0 ± 9.01 | -4.4 ± 7.66 |
The SDS is a subject-reported outcome measure that consists of a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when underproductive.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28) | -6.3 ± 7.54 | -5.3 ± 7.03 |
Onset of clinical response is defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in MADRS total score with onset by Day 2 that was maintained through Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Percentage of participants | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Percentage of Participants With Onset of Clinical Response | 6.5 | 1.6 |
Percentage of responders at the end of double-blind treatment phase (Day 28) were assessed. A participant was defined as a responder at a given time point if the percent improvement from baseline in MADRS total score is at least 50%. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Percentage of Responders | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Percentage of Responders at the End of Double-blind Treatment Phase (Day 28) | 19.3 | 16.0 |
Percentage of participants in remission at the end of double-blind treatment phase (Day 28) were assessed. A participant was considered as a remitter if participant had a MADRS total score of less than or equal to \[\<=\] 12 at a visit. MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Percentage of Participants | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28) | 12.8 | 10.4 |
Sustained remission is defined as the first occurrence of remission (MADRS Total score \<=12) that was maintained through the Day 28 assessment with one excursion prior to Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Percentage of Participants | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Percentage of Participants With Sustained Remission | 5.6 | 6.3 |
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S permits a global evaluation of the participant's condition at a given time. Negative change in score indicates improvement. The last post-baseline observation during the double-blind phase was carried forward as Endpoint.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | -1.0 (-5 to 1) | -1.0 (-5 to 1) |
The GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). The last post-baseline observation during the double-blind phase was carried forward as the "Endpoint".
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | -4.3 ± 5.65 | -2.9 ± 5.28 |
The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate problems, Level 4 indicating severe problems, and Level 5 indicating extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. Health Status Index ranges from -0.148 to 0.949, and is anchored at 0 (dead) and 1 (full health), a lower score indicates worse health.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index | 0.152 ± 0.2294 | 0.103 ± 0.2084 |
The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS) | 16.7 ± 20.47 | 11.9 ± 25.21 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.
| Units on a Scale | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD |
|---|---|---|
| Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score | -13.4 ± 18.83 | -9.5 ± 16.95 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 1/126 (0.8%) | 3/126 (2.4%) | 118/126 (93.7%) |
| Double-blind: Oral AD + Intranasal Placebo | 0/126 (0%) | 3/126 (2.4%) | 61/126 (48.4%) |
| Follow-up: Intranasal Esketamine+ Oral AD | 0/106 (0%) | 2/106 (1.9%) | 10/106 (9.4%) |
| Follow-up: Oral AD + Intranasal Placebo | 0/103 (0%) | 2/103 (1.9%) | 13/103 (12.6%) |
| Event | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | Double-blind: Oral AD + Intranasal Placebo | Follow-up: Intranasal Esketamine+ Oral AD | Follow-up: Oral AD + Intranasal Placebo |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/126 | 3/126 | 1/106 | 1/103 |
| Cholecystitis AcuteHepatobiliary disorders | 0/126 | 0/126 | 0/106 | 1/103 |
| Suicide AttemptPsychiatric disorders | 1/126 | 0/126 | 1/106 | 0/103 |
| Completed SuicidePsychiatric disorders | 1/126 | 0/126 | 0/106 | 0/103 |
| Event | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | Double-blind: Oral AD + Intranasal Placebo | Follow-up: Intranasal Esketamine+ Oral AD | Follow-up: Oral AD + Intranasal Placebo |
|---|---|---|---|---|
| DizzinessNervous system disorders | 97/126 | 25/126 | 0/106 | 1/103 |
| DissociationPsychiatric disorders | 75/126 | 8/126 | 0/106 | 1/103 |
| NauseaGastrointestinal disorders | 53/126 | 17/126 | 0/106 | 3/103 |
| Blood Pressure IncreasedInvestigations | 38/126 | 13/126 | 1/106 | 2/103 |
| HypoaesthesiaNervous system disorders | 25/126 | 1/126 | 0/106 | 0/103 |
| Vision BlurredEye disorders | 23/126 | 1/126 | 0/106 | 0/103 |
| VomitingGastrointestinal disorders | 23/126 | 2/126 | 0/106 | 2/103 |
| SomnolenceNervous system disorders | 20/126 | 11/126 | 0/106 | 1/103 |
| HeadacheNervous system disorders | 16/126 | 14/126 | 3/106 | 0/103 |
| DysgeusiaNervous system disorders | 14/126 | 6/126 | 0/106 | 1/103 |
| Age, Categorical(Participants) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 126 | 126 | 252 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| Mean | 36.8 ± 11.95 | 37.8 ± 12.36 | 37.3 ± 12.14 |
| Sex: Female, Male(Participants) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| Female | 58 | 55 | 113 |
| Male | 68 | 71 | 139 |
| Ethnicity (NIH/OMB)(Participants) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 121 | 124 | 245 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 112 | 112 | 224 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 12 | 9 | 21 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Intranasal Esketamine + Oral Antidepressant (AD) | Intranasal Placebo + Oral AD | Total |
|---|---|---|---|
| CHINA | 112 | 112 | 224 |
| UNITED STATES | 14 | 14 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Apr 2021, 34 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Depressive Disorder, Treatment-Resistant →
Janssen Research & Development, LLC →